In March 2025, the company introduced new strategies for a direct-to-buyer offering of its Wegovy weight loss drug. The company set up a completely new pharmacy, named NovoCare, which might demand customers $499 each month for usage of the drug, under fifty percent the cost of the drug by other pharmaceutical distribution networks.[fifty three]Than